search
Back to results

Coronary Arteriogenetic Heparinized Exercise (CARHEXA)

Primary Purpose

Refractory Angina, Chronic Stable Angina

Status
Completed
Phase
Not Applicable
Locations
Serbia
Study Type
Interventional
Intervention
Physical rehabilitation
Heparin
Placebo
Sponsored by
Clinical Centre of Serbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Refractory Angina focused on measuring No-option patients

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with documented coronary artery disease not amenable of future treatment and belonging to "no-option" category with symptoms consistent with angina pectoris

Exclusion Criteria:

  • Patients with unstable angina, recent myocardial infarction, uncontrolled hypertension, hemodynamically valvular heart disease, bronchial asthma, and neurologic and/or orthopedic illnesses that limit exercise capacity .
  • Patients receiving vitamin K antagonist.
  • Patients actively involved in programmes of cardiac rehabilitation or exercise training.

Sites / Locations

  • Clinical Centre of Serbia

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Heparin-primed physical rehabilitation

Placebo-primed physical rehabilitation

Arm Description

2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise

2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise

Outcomes

Primary Outcome Measures

Change from Baseline Canadian Cardiovascular Society (CCS) angina severity class at 2 weeks
CCS class ranging from 1 (mild) to 4 (severe) before and after the 2-week physical rehabilitation.

Secondary Outcome Measures

Change from Baseline peak stress wall motion score index (WMSI) at 2 weeks
Peak WMSI at stress echocardiography before and after 2-week physical rehabilitation at . Wall motion score index is assessed by using 17- segment model of left ventricle (1=normal, 4=dyskinetic).
Change from baseline peak stress global longitudinal strain (GLS) at 2 weeks
Peak stress GLS assessed by echocardiography before and after the 2-week physical rehabilitation.

Full Information

First Posted
November 8, 2017
Last Updated
May 12, 2020
Sponsor
Clinical Centre of Serbia
Collaborators
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
search

1. Study Identification

Unique Protocol Identification Number
NCT03350737
Brief Title
Coronary Arteriogenetic Heparinized Exercise
Acronym
CARHEXA
Official Title
Coronary ARteriogenesis With Combined Heparin and EXercise Therapy in Chronic Refractory Angina
Study Type
Interventional

2. Study Status

Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
February 1, 2013 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
December 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Clinical Centre of Serbia
Collaborators
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the addition of heparin to a 2-week cycle of physical rehabilitation in the treatment of refractory angina. Half of the patients will undergo heparin-primed physical rehabilitation, while the other half will undergo only physical rehabilitation.
Detailed Description
Our approach is based on the combination of pharmacological stimuli (with heparin) on top of a 2-week cycle of physical rehabilitation. The rationale for this chemical-physical cocktail stems from the fact that increase in shear stress (achieved with exercise), or heparin (when used alone) have no significant effect on coronary arteriogenesis. Nevertheless, when the two stimuli are coupled coronary arteriogenesis is consistently present, and clinically significant. The basic principle of heparin treatment is to potentiates angiogenic growth factors, which are over expressed by increased shear stress at the site of pre-existing collateral vessels as a result of exercise or pacing. Although the precise mechanisms by which heparin potentiates arteriogenesis remain to be completely elucidated, heparin administration combined with exercise has great potential in treating patients with effort angina who are not indicated for conventional revascularization therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Refractory Angina, Chronic Stable Angina
Keywords
No-option patients

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective, randomized, open-label study design. These "no-option" patients will be allocated (16 for each group) to 2 treatments
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Heparin-primed physical rehabilitation
Arm Type
Experimental
Arm Description
2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise
Arm Title
Placebo-primed physical rehabilitation
Arm Type
Placebo Comparator
Arm Description
2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise
Intervention Type
Other
Intervention Name(s)
Physical rehabilitation
Other Intervention Name(s)
E
Intervention Description
Standard treadmill exercise session
Intervention Type
Drug
Intervention Name(s)
Heparin
Other Intervention Name(s)
H
Intervention Description
Heparin i.v.
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
P
Intervention Description
Sodium Chloride 0.9% i.v.
Primary Outcome Measure Information:
Title
Change from Baseline Canadian Cardiovascular Society (CCS) angina severity class at 2 weeks
Description
CCS class ranging from 1 (mild) to 4 (severe) before and after the 2-week physical rehabilitation.
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Change from Baseline peak stress wall motion score index (WMSI) at 2 weeks
Description
Peak WMSI at stress echocardiography before and after 2-week physical rehabilitation at . Wall motion score index is assessed by using 17- segment model of left ventricle (1=normal, 4=dyskinetic).
Time Frame
2 weeks
Title
Change from baseline peak stress global longitudinal strain (GLS) at 2 weeks
Description
Peak stress GLS assessed by echocardiography before and after the 2-week physical rehabilitation.
Time Frame
2 weeks
Other Pre-specified Outcome Measures:
Title
Change from Baseline Coronary Collateral Circulation (CCC) at 2 weeks
Description
CCC score assessed by multi dimensional computed tomography (CT) before and after 2-week physical rehabilitation. Distal filling of the epicardial segment is semiquantitatively classified by using a four-point scale according to patterns at coronary CT angiography (CTA) (0 = absence of distal filling; 1 = partial distal filling, with a length less than one-third of the segment; 2 = partial distal filling, with a length between one-third and two-thirds of the segment; 3 = complete or partial distal filling, with a length longer than two-thirds of the segment). A coronary CTA scores correspond fully to Rentrop classification (coronary CTA score of 0 or 1 to Rentrop 0 or 1, coronary CTA score of 2 or 3 to Rentrop 2 or 3). Coronary CTA score of 3 is indicative of well-developed collaterals, contrary to scores of 0-2 (poorly developed). Also we look for change in growth of baseline bridging antegrade collaterals at 2 weeks (0= not present, 1= present)
Time Frame
2 weeks
Title
Change from Baseline Stable Angina questionnaire (SAQ) at 4 weeks
Description
19-item Seattle SAQ that assesses angina frequency, angina stability, physical limitations, treatment satisfaction, and disease perception/QoL
Time Frame
2 weeks to one month

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with documented coronary artery disease not amenable of future treatment and belonging to "no-option" category with symptoms consistent with angina pectoris Exclusion Criteria: Patients with unstable angina, recent myocardial infarction, uncontrolled hypertension, hemodynamically valvular heart disease, bronchial asthma, and neurologic and/or orthopedic illnesses that limit exercise capacity . Patients receiving vitamin K antagonist. Patients actively involved in programmes of cardiac rehabilitation or exercise training.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Branko Beleslin, MD, PhD
Organizational Affiliation
Clinical Centre of Serbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ana Djordjevic-Dikic, MD, PhD
Organizational Affiliation
Clinical Centre of Serbia
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Eugenio Picano, MD, PhD
Organizational Affiliation
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy
Official's Role
Study Chair
Facility Information:
Facility Name
Clinical Centre of Serbia
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data for all primary and secondary outcome measures will be made available.
IPD Sharing Time Frame
After the study completion.
IPD Sharing Access Criteria
For collaborators, data analyses upon request.
Citations:
PubMed Identifier
11078227
Citation
Barron HV, Sciammarella MG, Lenihan K, Michaels AD, Botvinick EH. Effects of the repeated administration of adenosine and heparin on myocardial perfusion in patients with chronic stable angina pectoris. Am J Cardiol. 2000 Jan 1;85(1):1-7. doi: 10.1016/s0002-9149(99)00596-2.
Results Reference
background
PubMed Identifier
14967718
Citation
Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, Antoniucci D. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation. 2004 Mar 9;109(9):1121-6. doi: 10.1161/01.CIR.0000118496.44135.A7. Epub 2004 Feb 16.
Results Reference
background
PubMed Identifier
9373049
Citation
Bombardini T, Picano E. The coronary angiogenetic effect of heparin: experimental basis and clinical evidence. Angiology. 1997 Nov;48(11):969-76. doi: 10.1177/000331979704801106.
Results Reference
background
PubMed Identifier
11390835
Citation
Buschmann I, Schaper W. Arteriogenesis Versus Angiogenesis: Two Mechanisms of Vessel Growth. News Physiol Sci. 1999 Jun;14:121-125. doi: 10.1152/physiologyonline.1999.14.3.121.
Results Reference
background
PubMed Identifier
2834115
Citation
Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation. 1988 May;77(5):1022-9. doi: 10.1161/01.cir.77.5.1022.
Results Reference
background
PubMed Identifier
12515758
Citation
Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003 Jan 7;107(1):149-58. doi: 10.1161/01.cir.0000047041.66447.29. No abstract available.
Results Reference
background
PubMed Identifier
11846493
Citation
Mannheimer C, Camici P, Chester MR, Collins A, DeJongste M, Eliasson T, Follath F, Hellemans I, Herlitz J, Luscher T, Pasic M, Thelle D. The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J. 2002 Mar;23(5):355-70. doi: 10.1053/euhj.2001.2706. No abstract available.
Results Reference
background
PubMed Identifier
19770393
Citation
Meier P, Gloekler S, de Marchi SF, Indermuehle A, Rutz T, Traupe T, Steck H, Vogel R, Seiler C. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation. 2009 Oct 6;120(14):1355-63. doi: 10.1161/CIRCULATIONAHA.109.866269. Epub 2009 Sep 21.
Results Reference
background
PubMed Identifier
12383579
Citation
Picano E, Alaimo A, Chubuchny V, Plonska E, Baldo V, Baldini U, Pauletti M, Perticucci R, Fonseca L, Villarraga HR, Emanuelli C, Miracapillo G, Hoffmann E, De Nes M. Noninvasive pacemaker stress echocardiography for diagnosis of coronary artery disease: a multicenter study. J Am Coll Cardiol. 2002 Oct 2;40(7):1305-10. doi: 10.1016/s0735-1097(02)02157-5.
Results Reference
background
PubMed Identifier
9093537
Citation
Picano E, Michelassi C. Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis. Cardiovasc Res. 1997 Mar;33(3):666-70. doi: 10.1016/s0008-6363(96)00262-3.
Results Reference
background
PubMed Identifier
11549300
Citation
Picano E; PISA (Persantin In Stable Angina) study group. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study. Eur Heart J. 2001 Oct;22(19):1785-93. doi: 10.1053/euhj.2001.2623.
Results Reference
background
PubMed Identifier
3156171
Citation
Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985 Mar;5(3):587-92. doi: 10.1016/s0735-1097(85)80380-6.
Results Reference
background
PubMed Identifier
19144878
Citation
Schirmer SH, van Nooijen FC, Piek JJ, van Royen N. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart. 2009 Mar;95(3):191-7. doi: 10.1136/hrt.2007.136119.
Results Reference
background
PubMed Identifier
19001473
Citation
Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, Voigt JU, Zamorano JL; European Association of Echocardiography. Stress Echocardiography Expert Consensus Statement--Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J. 2009 Feb;30(3):278-89. doi: 10.1093/eurheartj/ehn492. Epub 2008 Nov 11. No abstract available.
Results Reference
background
PubMed Identifier
11382729
Citation
Tateno S, Terai M, Niwa K, Jibiki T, Hamada H, Yasukawa K, Honda T, Oana S, Kohno Y. Alleviation of myocardial ischemia after Kawasaki disease by heparin and exercise therapy. Circulation. 2001 May 29;103(21):2591-7. doi: 10.1161/01.cir.103.21.2591.
Results Reference
background
PubMed Identifier
20855668
Citation
Traupe T, Gloekler S, de Marchi SF, Werner GS, Seiler C. Assessment of the human coronary collateral circulation. Circulation. 2010 Sep 21;122(12):1210-20. doi: 10.1161/CIRCULATIONAHA.109.930651. No abstract available.
Results Reference
background
PubMed Identifier
20432394
Citation
Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, Poulose AK, Traverse JH, Henry TD. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010 May 1;75(6):886-91. doi: 10.1002/ccd.22431.
Results Reference
background
PubMed Identifier
19736553
Citation
Wykrzykowska JJ, Henry TD, Lesser JR, Schwartz RS. Imaging myocardial angiogenesis. Nat Rev Cardiol. 2009 Oct;6(10):648-58. doi: 10.1038/nrcardio.2009.157. Epub 2009 Sep 8.
Results Reference
background

Learn more about this trial

Coronary Arteriogenetic Heparinized Exercise

We'll reach out to this number within 24 hrs